|
2025 Journal Article Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western CountriesArgollo, Marjorie, An, Yoon K., Azzam, Nahla, Balderramo, Domingo C., Fadeeva, Olga, Kuo, Chia-Jung, Laurent, Julie and Uy, Elenore (2025). Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western Countries. Advances in Therapy, 1-23. doi: 10.1007/s12325-025-03249-w |
|
2025 Journal Article Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s diseaseGilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Swe, Ei, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease. Intestinal Research. doi: 10.5217/ir.2024.00174 |
|
2025 Journal Article Su1943: CORRELATION OF BIOCHEMICAL, ENDOSCOPIC AND HISTOLOGIC ENDPOINTS IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIALPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline L., Redmond, Diane, Chan, Pak Wo, Mourad, Fadi H., Kermeen, Melissa and Leong, Rupert (2025). Su1943: CORRELATION OF BIOCHEMICAL, ENDOSCOPIC AND HISTOLOGIC ENDPOINTS IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIAL. Gastroenterology, 169 (1), S-900. doi: 10.1016/s0016-5085(25)03004-5 |
|
2025 Journal Article Su1947: COMPARATIVE ACCURACY AND RELIABILITY OF HANDHELD VERSUS CART-BASED ULTRASOUND IN ASSESSING INFLAMMATORY BOWEL DISEASE ACTIVITYKhaing, Myat Myat, Fernandes, Richard G., An, Yoon-Kyo, Baraty, Brandon, Bryant, Robert V., Ghaly, Simon, Smith, Rebecca, Srinivasan, Ashish, Hay, Karen and Begun, Jakob (2025). Su1947: COMPARATIVE ACCURACY AND RELIABILITY OF HANDHELD VERSUS CART-BASED ULTRASOUND IN ASSESSING INFLAMMATORY BOWEL DISEASE ACTIVITY. Gastroenterology, 169 (1), S-902. doi: 10.1016/s0016-5085(25)03008-2 |
|
2025 Journal Article Mo1954: CONSISTENCY AND QUALITY OF INFLAMMATORY BOWEL DISEASE CARE IN AUSTRALASIA; TOWARDS BENCHMARKINGSu, Wai Kin, McNamara, Jack, Wilson, William E., Wark, Gabrielle, Lynch, Kate D., Su, Heidi Y., Forbes, Angela J., Lawrance, Ian C., An, Yoon-Kyo, Dutt, Shoma, Brett, Laurel, Walker, Gareth, Andrews, Jane M., Connor, Susan J. and Ghaly, Simon (2025). Mo1954: CONSISTENCY AND QUALITY OF INFLAMMATORY BOWEL DISEASE CARE IN AUSTRALASIA; TOWARDS BENCHMARKING. Gastroenterology, 169 (1), S-1240. doi: 10.1016/s0016-5085(25)03741-2 |
|
2025 Journal Article Su1899: EXTENSIVE DISEASE CLEARANCE AS A NOVEL COMPOSITE ENDPOINT TO PREDICT LONG-TERM RELAPSE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIALPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline L., Redmond, Diane, Chan, Pak Wo, Mourad, Fadi H., Kermeen, Melissa and Leong, Rupert (2025). Su1899: EXTENSIVE DISEASE CLEARANCE AS A NOVEL COMPOSITE ENDPOINT TO PREDICT LONG-TERM RELAPSE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIAL. Gastroenterology, 169 (1), S-879. doi: 10.1016/s0016-5085(25)02960-9 |
|
2025 Journal Article The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoringGilmore, Robert, Fernandes, Richard, Schildkraut, Tamar, Joshi, Riddhi, Lin, Lyman, Vorgin, Sara, Etchegaray, Amirah, Shanmuga Anandan, Aathavan, Tambakis, George, Loebenstein, Moshe, An, Yoon-Kyo, Begun, Jakob and Wright, Emily K (2025). The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring. Crohn's and Colitis 360, 7 (2) otaf028, 1-9. doi: 10.1093/crocol/otaf028 |
|
2025 Journal Article Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for ConcernSuo, Paulina, Srinivasan, Ashish, Thin, Lena, An, Yoon‐Kyo, Fernandes, Richard G., Ghaly, Simon, Jeffrey, Angus W., Menon, Shankar, Olsen, Nicholas, Skinner, Thomas, van Langenberg, Daniel R., Winston, James and Haifer, Craig (2025). Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern. Journal of Gastroenterology and Hepatology, 40 (5), 1174-1181. doi: 10.1111/jgh.16916 |
|
2025 Conference Publication Clinical outcomes and predictive factors differ in acute severe ulcerative colitis for East Asian and Western patientsKim, E. S., Lee, H. S., Kim, D. H., Kim, H. S., Park, S. H., Kim, K. O., Jang, B., Kim, D. S., Lee, Y. J., Song, E. M., Kim, S. J., Lee, J., Yang, C. H., Sagami, S., Kobayashi, T., Mak, J., Liu, J., Cao, Q., Lin, W. C., Wei, S. C., Rice, K., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R. G., Gilmore, R., Vasudevan, A., Zhang, J., Brownson, A. ... Garg, M. (2025). Clinical outcomes and predictive factors differ in acute severe ulcerative colitis for East Asian and Western patients. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/ecco-jcc/jjae190.0082 |
|
2025 Journal Article Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease CoalitionAkyüz, Filiz, An, Yoon Kyo, Begun, Jakob, Aniwan, Satimai, Bui, Huu Hoang, Chan, Webber, Choi, Chang Hwan, Chopdat, Nazeer, Connor, Susan J, Desai, Devendra, Flanagan, Emma, Kobayashi, Taku, Lai, Allen Yu-Hung, Leong, Rupert W, Leow, Alex Hwong-Ruey, Leung, Wai Keung, Limsrivilai, Julajak, Muzellina, Virly Nanda, Peddi, Kiran, Ran, Zhihua, Wei, Shu Chen, Sollano, Jose, Teo, Michelle Mui Hian, Wu, Kaichun, Ye, Byong Duk and Ooi, Choon Jin (2025). Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition. Intestinal Research, 23 (1), 37-55. doi: 10.5217/ir.2024.00089 |
|
2025 Conference Publication Consistency and Quality of Inflammatory Bowel Disease care in Australasia; Towards Benchmarking, Crohn’s Colitis Cure Data Insight’s ProgramSu, W. K., McNamara, J., Wilson, W., Wark, G., Lynch, K., Su, H., Forbes, A., Lawrance, I., An, Y. K., Dutt, S., Brett, L., Walker, G., Andrews, J. M., Connor, S. J. and Ghaly, S. (2025). Consistency and Quality of Inflammatory Bowel Disease care in Australasia; Towards Benchmarking, Crohn’s Colitis Cure Data Insight’s Program. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0054 |
|
2025 Conference Publication Handheld ultrasound devices are an accurate alternative to cart-based ultrasound for IBD disease activity assessmentFernandes, R., Swe, E., Khaing, M. M., Gilmore, R., Khoo, E., An, Y. K. and Begun, J. (2025). Handheld ultrasound devices are an accurate alternative to cart-based ultrasound for IBD disease activity assessment. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.1349 |
|
2025 Conference Publication The real-world use of intravenous and subcutaneous Vedolizumab in IBD across Australia and New Zealand, Crohn’s Colitis Cure Data Insight’s ProgramSu, W. K., Wilson, W., Wark, G., Ghaly, S., Lynch, K., Lawrance, I., Walker, G., Forbes, A., Brett, L., An, Y. K., Connor, S. J. and Andrews, J. M. (2025). The real-world use of intravenous and subcutaneous Vedolizumab in IBD across Australia and New Zealand, Crohn’s Colitis Cure Data Insight’s Program. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0777 |
|
2025 Conference Publication Janus Kinase Inhibitors for the Management of Acute Severe Ulcerative Colitis: A Multicentre StudyGilmore, R., Fernandes, R., Chin, S., Con, D., De Cruz, P., Demase, K., Sparrow, M., Thin, L., Baker, J., Venugopal, K., Lucas, S., Garg, M., Loebenstein, M., Nguyen, A., Moore, G., Tandon, B., Bryant, R., MacFarlane, K., Lynch, K., Abdul, S., Subhaharan, D., Mohsen, W., Haig, A., Day, M., White, L., Begun, J. and An, Y. K. (2025). Janus Kinase Inhibitors for the Management of Acute Severe Ulcerative Colitis: A Multicentre Study. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.1203 |
|
2025 Conference Publication Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trialPudipeddi, A., Dhanji, P., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D., Chan, W., Mourad, F., Kermeen, M. and Leong, R. (2025). Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trial. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0431 |
|
2024 Journal Article Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort studyGilmore, Robert, Fernandes, Richard, Hartley, Imogen, Arzivian, Arteen, Leong, Rupert, Andrew, Bridgette, Vasudevan, Abhinav, Greeve, Tessa, Moore, Gregory Thomas, Kim, Steven, Lightowler, Daniel, Singh, Abhey, Mahy, Gillian, Mithanthaya, Aditya, Venugopaul, Kannan, Han, Sangwoo, Bryant, Robert, West, Jack, Segal, Jonathan, Christensen, Britt, Corte, Crispin, Ding, Nik, An, Yoon-Kyo and Begun, Jakob (2024). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research. doi: 10.5217/ir.2024.00127 |
|
2024 Conference Publication Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated AnemiaBisht, Kavita, An, Yoon-Kyo, Shatunova, Svetlana, Wang, Ran, Barbier, Valerie, Giri, Rabina, Amiss, Anna, Tang, Yifu, Alexander, Kylie, Millard, Susan, Winkler, Ingrid G., Pettit, Allison, Begun, Jakob and Levesque, Jean-Pierre (2024). Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-193349 |
|
2024 Journal Article Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trialPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark G., De Cruz, Peter, Fung, Caroline Lan-San, Redmond, Diane, Chan, Webber, Mourad, Fadi, Kermeen, Melissa and Leong, Rupert W. (2024). Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial. Clinical Gastroenterology and Hepatology, 22 (11), 2299-2308. doi: 10.1016/j.cgh.2024.04.019 |
|
2024 Conference Publication Documented variation in inflammatory bowel disease care in Australasia : Crohn's Colitis Cure (CCC) data insights programSu, Wai Kin, Mcnamara, Jack, Pipicella, Joseph, Wilson, William, Ghaly, Simon, Cabaero, Aura Gesha, Walker, Gareth, Forbes, Angela, Su, Heidi, Brett, Laurel, Dutt, Shoma, An, Yoon-Kyo, Lawrance, Ian, Lynch, Kate, Andrews, Jane and Connor, Susan J. (2024). Documented variation in inflammatory bowel disease care in Australasia : Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case seriesSwe, Ei Phyu Phyu, Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2024). Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
